A comprehensive view of Phase 3 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA accepts for priority review GSK’s application for an expanded indication of Jemperli dostarlimab-gxly plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Published: April 24, 2024 by GSK Group (GlaxoSmithKline)
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published: April 19, 2024 by EquityBites
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Eli Lilly reports tirzepatide injectable significantly reduced sleep apnea in Phase 3 trials, achieving up to 63% reduction in the apnea-hypopnea index, a measure of sleep apnea severity; the drug also led to significant weight loss
Published: April 17, 2024 by Eli Lilly & Co.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count